#3 - UnitedHealth Group (NYSE:UNH)
The healthcare sector is a good place to look for long-term stocks. One of the best options for investors is UnitedHealth Group Inc. (NYSE: UNH). UnitedHealth is one of the leading providers of health insurance mandated by the Affordable Care Act (ACA) health marketplaces. It’s also one of the leading providers of Medicare Advantage plans.
The aging of America will continue to be a driver of growth. Even if Medicare-for-all doesn’t become a reality, Medicare-for-most is a near certainty. In fact, the Centers for Medicare and Medicaid Services projects that Medicare spending growth will average 7.2% between 2021 and 2030, the fastest rate among the major payers.
Over the past five years, UNH stock has delivered a total return of around 150% to investors. That’s slightly above the S&P 500 over that time. It’s also down sharply from the pace of growth for the stock in the last 10 years. However, the company has a growing base of customers that is allowing it to beat revenue and earnings on a year-over-year (YOY) basis.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Read More - Current Price
- $592.18
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 19 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $615.53 (3.9% Upside)